Adalimumab (ADM)

Humira

Adalimumab (ADM)
Adalimumab is a TNF inhibiting anti-inflammatory drug. AbbVie's trade name is derived from the acronym of "human monoclonal antibody in rheumatoid arthritis" (HUMIRA). Adalimumab binds to tumor necrosis factor-alpha (TNFα), preventing it from activating TNF receptors; TNFα inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases.Adalimumab, like other TNF inhibitors, infliximab, etanercept, certolizumab pegol and golimumab, may be used in the treatment of several conditions where the suppression of the immune response is desired. Not all the listed applications have been approved worldwide.Because adalimumab suppresses TNF, which is part of the immune system, latent infections, such as tuberculosis, can be reactivated, and the immune system may be unable to fight new infections.

Organism species: Pan-species (General)